Revolution Medicines

RVMD

Market cap $33.5B

Results simultaneously published in The New England Journal of Medicine Results simultaneously published in The New England Journal of Medicine

Revolution Medicine's experimental pancreatic cancer pill doubled survival compared with chemotherapy and improved symptoms enough that some patients could resume ​activities they had previously abandoned, setting a new benchmark for this deadly cancer, researchers reported on Sunday.

REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that members of Revolution Medicines' senior management team will host a webcast on Sunday, May 31 at 7:00 pm ET to discuss positive results from the Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) following presentation of the data during the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

GraniteShares has filed with the U.S. Securities and Exchange Commission to launch three new leveraged single-stock ETFs tied to high-volatility themes spanning nuclear energy, AI infrastructure and biotech.

U.S. cancer centers are moving quickly to enroll patients in an expanded access program for a pancreatic cancer drug developed by Revolution Medicines Inc. (NASDAQ:RVMD) after clinical trial results showed the treatment significantly extended survival in patients with advanced disease.

U.S. cancer centers are scrambling to enroll patients in an early access program for a highly promising pancreatic cancer drug from ​Revolution Medicines while they await what they hope will be a speedy FDA approval.

Revolution Medicines posts a wider Q1 loss and raises its 2026 expense outlook as R&D and commercial prep costs climb.

Revolution Medicines, Inc. (RVMD) Q1 2026 Earnings Call Transcript

Data contributed to the scientific and clinical rationale for RASolute 302, a pivotal Phase 3 trial in second line treatment of patients with metastatic pancreatic cancer Data contributed to the scientific and clinical rationale for RASolute 302, a pivotal Phase 3 trial in second line treatment of patients with metastatic pancreatic cancer

An experimental drug from Revolution Medicines that nearly ​doubled survival time for patients with advanced pancreas cancer in clinical trials comes with a high rate ‌of mostly low-grade side effects, researchers reported on Wednesday.